At King’s, we’re proud to have created an innovation ecosystem that nurtures academic researchers to spin out companies offering life-changing technologies and services. In 2022, Beauhurst ranked King’s College London 2nd in London, and 4th amongst UK universities by total spinout equity raised. 

Our track record reflects King’s world-class facilities, research creativity and support for academic entrepreneurship.

Explore how our recent spinouts have scaled beyond academia into independent business ventures. Contact details for specific spinouts can be found on their respective websites, if you’d like to find out more.

Adaptate Biotherapeutics

Adaptate BioTherapueutics was a pharmaceutical company developing an innovative portfolio of antibody-based immunotherapies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells in situ. Their targeted approach offered the potential to safely and effectively address the challenges often encountered by current cancer immunotherapies. Adaptate was acquired by Takeda Pharmaceutical Company in 2022.

AviadoBio (formerly Neurogeneus)

AviadoBio has developed a next-generation AAV gene therapy platform focused on controlling gene expression with a suite of unique delivery solutions that deliver gene therapies directly to the brain and spinal cord. We are also building additional platforms and capabilities as well as proprietary RNA silencing and subpial delivery technologies. Our neuroanatomy-led approach to viral vector distribution seeks to deliver our therapies to the right place to maximize their potential. These potentially life-changing gene therapies aim to help people living with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Cytolytix

Cytolytix was established to progress the triple negative breast cancer project, CLX001, through preclinical development to a stage of readiness for clinical trials. CLX001 is a peptide in a nanoparticle formulation that is designed for the precision destruction of cancer cells. Cytolix is a partially-owned ValiRx subsidiary, which signed an IP license agreement with King's College London.

Epsilogen (formerly IGeM Therapeutics)

Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. Evolved to treat parasitic infection, IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. Epsilogen has constructed a novel and proprietary pipeline of anti-cancer IgE and IgE-derivative antibodies with enhanced functionality.

GammaDelta

Gamma Delta therapeutics worked to exploit the unique activities of gamma delta (γδ) T cells that are found in the body's tissues where cancers and inflammatory diseases take hold. Using these distinct immune cells, the company was able to develop “off-the-shelf” cell therapies that recognise and are activated by molecular patterns of dysregulation. GammaDelta was acquired by Takeda in 2021.

Heqet Therapeutics

Heqet Therapeutics develops first-in-class non-coding RNA-based compounds to address highly unmet medical needs in heart attacks and other cardiovascular diseases. Survival rates from heart failure prognosis are poor, with 60% of patients dying within 4 years from diagnosis. Heqet Therapeutics aims to advance the pharmacological treatment of heart failure, which has not drastically progressed in the last 30 years.

Leucid Bio

Leucid Bio is a biotech company pioneering next-generation cell therapies for hard-to-treat cancers. CAR T-cell therapy is revolutionary technology where patients’ own immune cells, called T-cells, are reprogrammed to recognise and destroy cancer cells. Ninety percent of cancers are solid tumours and are becoming the leading cause of death in the West. Leucid Bio has developed an integrated approach to CAR T-cell treatment of solid tumours.

Pheon Therapeutics (formerly Femtogenix)

Pheon Therapeutics is a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers. ADCs consist of an antibody that is chemically linked to a cytotoxic payload to deliver potent cytotoxic agents directly to cancer cells. ADCs are rapidly gaining clinical and commercial momentum, with 13 ADCs already approved by the FDA and more than 100 ADCs in clinical trials.

Planet Biotechnology

Planet Biotechnology produced the first plant-made antibody, or ‘plantibody’, ever tested in a clinical trial. They are continuing to develop and commercialise new antibody-based therapeutic and preventative products through cultivation of genetically modified green plants to address unmet medical needs.

Quell Therapeutics

Quell Therapeutics are developing therapies addressing a range of autoimmune and inflammatory diseases, as well as preventing rejection in organ transplantation. Quell is employing proprietary and innovative technologies to genetically enhance Tregs (T regulatory cells) that can be introduced into patients with the potential to control unwanted immune activity.

ReNeuron

ReNeuron concentrated on the research, development and commercial exploitation of therapeutics for neurological diseases and conditions. They developed a technology platform that produced exosomes with unique tissue targeting tropisms to deliver a payload of choice to a preferred cell type.

Revolo Biotherapeutics

Revolo Biotherapeutics is developing autoimmune and allergic disease treatments by resetting the immune system for superior disease remission. Current therapies for autoimmune and allergic diseases often provide only short-term relief while suppressing the immune system, which puts patients at risk of serious infection and life-threatening side effects. Revolo uses novel macrophage and monocyte biology to target modify both the regulatory and effector arms of the immune system.

Transcriptogen

Transcriptogen develops medical therapies for disease using molecules that inhibit transcription, the first step in copying DNA for creating proteins. It is currently creating treatments for cancer, in particular breast and pancreatic cancer tumours, and plans to expand into other areas.

Centron Diagnostics

Centron Diagnostics Ltd developed an accurate, automatic, non-invasive medical device to measure both peripheral blood pressure and central systolic blood pressure. The device uses a novel, patented method that allows both measurements to be performed in one simple operation and will allow this important measurement to be taken into routine clinical use. Centron Diagnostics was acquired by SunTech Medical in July 2014.

deltaDOT

deltaDOT design and produce patented methods and instrumentation in High Performance Capillary Electrophoresis (HPCE). HPCE is applied in Life Sciences research, drug testing, diagnostics and bio-pharmaceutical manufacturing. This technology is used in detection, separation and analysis of proteins, nucleic acids, carbohydrates, viruses and bacteria, chemicals and a wide range of other analytes.

LiDCO

LiDCO supplied noninvasive and minimally invasive hemodynamic equipment to monitor the amount of blood flowing around the body and ensure that vital organs had enough oxygen. Clinical studies showed that optimising the hemodynamic status of high-risk patients produces better outcomes and reduced hospital stay. Lidco was acquired by Masimo in 2021.

MedPharm

MedPharm is a global Contract Development and Manufacturing Organisation (CDMO) that provides topical and transdermal product design, development, and manufacturing services. Medpharm specialises in drug delivery products for skin, nails, eyes, ears, airways and mucosal membranes. Medpharm merged with Tergus Pharma in June 2024.

Oxvent

OxVent is a high-performance, medical-grade, mechanical ventilator that is inexpensive, quick to manufacture, rapid to deploy and scalable. It is ideally suited for emergency situations (like the COVID-19 pandemic), and low-resource settings (for example in developing countries), and routine procedures requiring general anaesthesia.

Reminova

Reminova developed new treatments for tooth decay using a small electrical charge to encourage re-mineralisation of the tooth, for use by dentists. Their painless remineralisation process involved no drilling, no filling and no need for anaesthetic injections.

SpOtOn Clinical Diagnostics

SpOtOn Clinical Diagnostics develops technology based on mass spectrometry in clinical biochemistry. They have adopted mass spectrometry for newborn and ante-natal screening for haemoglobinopathies, as well as screening and monitoring inherited metabolic diseases. In addition, SpOtOn can track kidney function based on the in-depth knowledge gleaned from supporting the world-leading paediatric renal service at Evelina Children’s Hospital.

Zeus Sleep

Zeus Sleep is an anti-snore device developed in partnership with leading sleep doctors especially for throat snorers. Comfortable and unobtrusive, Zeus gently stimulates the tongue muscles to open airways, the root cause of snoring, to aid uninterrupted sleep. This high-tech device, trialled and tested by sleep apnoea and support charity Hope2Sleep, tackles snoring at its source improving the lives of snorers and their partners alike.

Cydar Medical

Cydar Medical provides regulated cloud-based AI clinical applications within an enterprise data architecture to support healthcare organisations with improved image-guided surgery. Their applications reduce hardware and software update expenses and streamline operations and workflows within hospitals.

Imanova

Imanova developed clinical imaging technology designed to improve the process of pharmaceuticals development. Imanova was a world leader in the development of novel imaging biomarkers and analysis techniques and their application in clinical academic research and translational drug development. Imanova was acquired by Invicro LLC in 2017.

Neuronostics

Neuronostics is innovating the way neurological conditions are diagnosed, treated, and monitored. They use the power of mathematical modelling to develop novel digital biomarkers that create faster paths to diagnosis and effective treatment. Their cloud-based support tool supports diagnosis from the first EEG, informs the best care pathway, and works on EEGs with no epileptiform activity.

Hypervision Surgical

Hypervision Surgical’s goal is to equip clinicians with advanced computer-assisted tissue analysis for improved surgical precision and patient safety, based on safe light alone. With expertise in interventional imaging, AI and medical devices, Hypervision Surgical have designed an intraoperative imaging system that integrates into the surgical workflow and is capable of wide-field, real-time, data-driven tissue characterisation.

VitaeVR

Vitae VR researches and develops a virtual reality product, called Vstore, designed to diagnose cognitive diseases such as dementia. Researchers at King’s have conducted 4 studies over 5 years across over 400 healthy participants and patients, into the efficacy of Vstore as a cognitive assessment tool.